Enhancing Survival and Minimizing Toxicity: Leveraging New Research in HER2+ and HR+/HER2- Breast Cancers

ONLINEHER2



Date & Location
Tuesday, November 17, 2020, 12:00 AM - Wednesday, November 17, 2021, 11:59 PM

Target Audience
Specialties - Anesthesia/Pain Management, Behavioral Sciences, Breast Medical Oncology, Cancer Prevention, Cardiology, Clinical Research, Critical Care, Developmental Therapeutics, Diagnostic Radiology, Emergency Medicine, Endocrinology/Endocrine Neoplasia, Epidemiology, Family Medicine, Gastroenterology, Gastrointestinal Medical Oncology, General Oncology, Genetics/Genomics, Genitourinary Medical Oncology, Gynecologic Oncology, Hospice/Palliative Care, Informatics, Internal Medicine, Interventional Radiology, Leukemia, Lymphoma/Myeloma, Melanoma/Skin Cancers, Neuro-oncology, Nuclear Medicine, Ophthalmology, Other, Pathology/Lab Medicine, Pediatrics/AYA, Plastic Surgery, Pulmonology, Radiation Oncology, Rehabilitation Medicine, Sarcoma , Stem Cell Transplantation, Surgical Oncology, Survivorship , Thoracic/Head and Neck
Professions - Nurse/APN, Physician (MD or DO)

Credits
AMA PRA Category 1 Credits™ (4.50 hours), Non-Physician Attendance (4.50 hours)

Overview
Enhancing Survival and Minimizing Toxicity: Leveraging New Research in HER2+ and HR+/HER2- Breast Cancers is a 4.50 hour internet enduring activity designed to deliver knowledge-based education regarding novel and emerging therapies as well as competency focused education to support precision medicine for breast cancer patients.


Objectives
At the conclusion of this educational activity, the participant should be able to:

  1. Describe new strategies being employed or under study to minimize toxicities in early breast cancer
  2. Explain how novel drug classes, either recently approved or nearing FDA approval, are influencing the treatment of metastatic breast cancer
  3. Discuss the mechanisms of action and key features of novel agents for breast cancer with recent FDA approval or nearing FDA approval

Accreditation
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Additional Information

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.